Prevalence of BRCA and VUS Mutations in Patients with Ovarian Cancer Treated at Oncosalud - AUNA

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Ovarian Cancer
Cancer Biology
Presenter Claudio Flores
Citation Annals of Oncology (2018) 29 (suppl_9): ix79-ix86. 10.1093/annonc/mdy436
Authors C. Flores1, P.P. Carrion Calderon2
  • 1Investigation, oncosalud, LIMA 41 - LIMA/PE
  • 2Lima, Clínica Oncosalud, LIMA 5 - Lima/PE



There are several studies that show the importance of the relationship of the presence of the BRCA1 - 2 gene mutation in ovarian cancer with the ancestral roots of the patients, showing a higher prevalence in those with Latin American roots, but with studies carried out in the United States and Mexico. In our country, prevalence studies in BRCA were performed in patients with breast cancer, but none in ovarian cancer. We reported the prevalence of BRCA 1-2 gene mutation and VUS (variant of uncertain significance) in a private Health Institution (Oncosalud-AUNA).


We selected all those patients who came from outpatient clinic and/or hospitalization at Oncosalud Clinic with histological diagnosis of high grade ovarian cancer (previously or non previously treated) between June 2017 to June 2018, who were tested for BRCA mutation in peripheral blood.


During the study period 62 patients with ovarian cancer had BRCA study. At diagnosis, the median age was 54 years (range: 33, 87) and 33.3% have more than 60 years. We found prevalence of BRCA mutation in 22.5% of 62 patients (BRCA-1: 17.7% and BRCA-2: 4.8%) and VUS in 8% (VUS BRCA-1: 3.2% and VUS BRCA-2: 4.8%). Of these patients, 25% had no children, 25% had abortions, 36.7% used oral contraceptives and only 5% had hormone replacement therapy. 11.7% had a personal history of breast cancer and 35% family history of breast, ovarian, colorectal or pancreatic cancer. Patients without personal o family history of cancer, had a prevalence of BRCA mutation in 12% and 9% in VUS.


This is the first report of prevalence of BRCA and VUS mutation in a Peruvian population, results were similar to other cohorts with a higher prevalence of BRCA-1 mutation than BRCA-2 mutation. The relevance of this study prevails in knowing that BRCA mutation confers a better prognosis, since the presence of this gene had a predictive factor of greater sensitivity to the combined treatments of platinum-based chemotherapy and also the possibility to use PARP inhibitors not only for treatment, also maintenance which confers a major PFS.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study



Has not received any funding.


All authors have declared no conflicts of interest.